BilliontoOne Snaps Up $125 Million

<p><strong><span class&equals;"xn-location">MENLO PARK <&sol;span><&sol;strong>&&num;8212&semi; BillionToOne&comma; Inc&period;&comma; a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all&comma; has closed an oversubscribed Series C funding round of <span class&equals;"xn-money">&dollar;125 million<&sol;span>&period; This round was co-led by incoming investor Adams Street Partners and existing investor Hummingbird Ventures with significant participation from Baillie Gifford&comma; Neotribe Ventures&comma; Norwest Venture Partners&comma; Civilization Ventures&comma; Fifty Years VC&comma; Pacific 8 Ventures&comma; Time BioVentures&comma; and Libertus Capital&comma; among others&period;<&sol;p>&NewLine;<div class&equals;"col-sm-10 col-sm-offset-1">&NewLine;<p>BillionToOne&&num;8217&semi;s molecular counting technology increases the resolution of disease detection using cell-free DNA by over 1000-fold&period; This technology is at the core of the Company&&num;8217&semi;s products&period; BillionToOne&&num;8217&semi;s flagship product&comma; UNITY Screen&comma; is the only non-invasive prenatal test &lpar;NIPT&rpar; that can assess fetal risk for common recessive conditions and aneuploidies from one maternal blood sample&period; According to an independent peer-reviewed publication &lpar;<u>Choates<&sol;u> et al&period;&comma; 2020&rpar;&comma; less than half of male partners go through traditional carrier screening when indicated&comma; limiting the identification of at-risk pregnancies&period; UNITY Screen™ does not require a paternal sample to assess fetal risk&comma; supporting greater equity in care&period; The Company has been growing its market share at an exponential pace&comma; with test volumes increasing more than 300&percnt; year over year in the fiscal year 2021&period; BillionToOne is applying this same molecular counting technology to a groundbreaking liquid biopsy test that combines treatment selection with monitoring&period; This test is slated to launch this year&period;<&sol;p>&NewLine;<&sol;div>&NewLine;<div class&equals;"col-sm-10 col-sm-offset-1">&NewLine;<p>This Series C funding will be used to expand BillionToOne&&num;8217&semi;s commercial and clinical teams&comma; scale up lab capacity&comma; and conduct clinical studies for their liquid biopsy test&period; &&num;8220&semi;Our prenatal test is solving a critical unmet medical need&period; We continue to grow at an incredible rate&comma; and we are building out an ever-increasing set of larger laboratory facilities&period; The current funding will be used to support our prenatal test growth while launching our differentiated liquid biopsy test that will transform oncology care&comma;&&num;8221&semi; said <span class&equals;"xn-person">Oguzhan Atay<&sol;span>&comma; Ph&period;D&period;&comma; co-founder and CEO of BillionToOne&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We have partnered with BillionToOne since their Series A in 2019&comma; and it has been incredible to witness the Company&&num;8217&semi;s tremendous growth and unparalleled execution&period; BillionToOne has experienced a significant expansion in terms of test volume and team members despite a pandemic&period; This is not by accident&period; The Company has an extremely talented and diverse team and a powerful technology platform&period; This unique combination will lead BillionToOne to revolutionize molecular diagnostics&comma;&&num;8221&semi; said <span class&equals;"xn-person">Firat Ileri<&sol;span> at Hummingbird Ventures&comma; a board member and one of the lead investors at BillionToOne&period;<&sol;p>&NewLine;<p><span class&equals;"xn-person">Thomas Bremner<&sol;span> from Adams Street Partners&comma; who is joining BillionToOne&&num;8217&semi;s Board of Directors&comma; adds&comma; &&num;8220&semi;BillionToOne&&num;8217&semi;s truly differentiated technology&comma; product lines that enable it to grow with higher efficiency&comma; execution in the prenatal market&comma; and plans for the oncology sector are exactly the kinds of traits we look for in companies that we invest in&period; We have great confidence around their growth trajectory and look forward to the next phase as they build a category-defining molecular diagnostics company&period;&&num;8221&semi;<&sol;p>&NewLine;<&sol;div>&NewLine;